Skip to main content

$0.120 0.010 (9.09%)

High

$0.12

Low

$0.11

Trades

74

Turnover

$139,612

Volume

1,216,523
30 June 2023 at 4:10pm
Register to track CAN and receive email alerts.
Subject
CAN Ann: Cann and Emyria mutually end collaboration

CAN Ann: EMD: Emyria and Cann Mutually End Collaboration

CAN Ann: Correction to Notice of Meeting

CAN Ann: Notice of General Meeting & Proxy Form

CAN Ann: Notification of cessation of securities - CAN

CAN Ann: Completion of placement of $10.0m

CAN Ann: Notice under section 708A(5)(e) Corporations Act

CAN Ann: Application for quotation of securities - CAN

CAN Ann: Revised timing for settlement of placement

CAN Ann: Update - Proposed issue of securities - CAN

CAN Ann: Notice under section 708(5)(e) Corporations Act

CAN Ann: Application for quotation of securities - CAN

CAN Ann: Proposed issue of securities - CAN

CAN Ann: Quarterly Activities/Appendix 4C Cash Flow Report

CAN Ann: Proposed issue of securities - CAN

CAN Ann: Investor presentation regarding capital raising

CAN Ann: Capital raising announcement

CAN Ann: Investor webinar

CAN Ann: Trading Halt

CAN Ann: Update on recovery of missing funds

CAN Ann: Cann provides further revenue update

CAN Ann: Notice under section 708(5)(e) of the Corporations Act

CAN Ann: Appendix 2A - Quotation of shares

CAN Ann: Proposed issue of Securities - CAN

CAN Ann: Shipment of significant first order to German partner iuvo

CAN Ann: Appendix 4C - quarterly

CAN Ann: Recall of product

CAN Ann: Initial Director's Interest Notice

CAN Ann: Appointment of new director

CAN Ann: Cann and Emyria investor webinar

CAN Ann: EMD: Emyria and Cann Group Investor Webinar

CAN Ann: Cann commences proceeding in Hong Kong to recover funds

CAN Ann: EMD: Emyria and Cann Partner to Register CBD Product

CAN Ann: Cann and Emyria partner to register CBD product

CAN Ann: Notice under section 708A(5(e) of the Corporations Act

CAN Ann: Cann completes acquisition of Satipharm business

CAN Ann: Appendix 2A - Issue of shares for Satipharm acquisition

CAN Ann: Cann supplies medicinal cannabis for clinical trial

CAN Ann: Cann Group - Half yearly investor presentation

CAN Ann: Cann releases half-year results - 31 December 2020

CAN Ann: Half Yearly Report and Accounts

CAN Ann: HY21 Results - investor webinar

CAN Ann: Notice under s708A(5)(e) - issue of shares

CAN Ann: Appendix 2A - Issue of shares to CSIRO

CAN Ann: Appendix 2A - Exercise of options

CAN Ann: Proposed issue of Securities - CAN

CAN Ann: Replacement Appendix 2A

CAN Ann: Notice under s.708A(5)(e)

CAN Ann: Federal Court orders granted

CAN Ann: Trading Halt

Register to track CAN and receive email alerts.

Similar Companies

CPH
EOF
IHL
MVP
MYX
NEU
PBP
RCE
SPL